Full Press Release Details
Pipeline with Initiation of Pre-clinical Study in Autism
TIKVAH, Israel - June 10, 2014 - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult
stem cell technologies for neurodegenerative diseases, today announced that it has initiated a study in a mouse model of autism
at the Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, under the direction of Professor
Daniel Offen. The study will explore the effects of the company's "MSC-NTF" cells on mouse behavior.
The study, which will
be conducted using the BTBR mouse model for autism, will investigate repetitive behavior, increased cognitive flexibility and improved
sociability in mice after administration of a single intracerebroventricular injection of the cells.
Autism is a spectrum
of disorders characterized by marked abnormalities in communication and social interactions. Stem cell-based regenerative therapy
has been proposed for the treatment of autism, as studies have shown that cell transplantation may affect molecular processes associated
with autism pathophysiology. In addition, immune dysfunction has been confirmed with autistic children, and mesenchymal stem cells
are known to regulate the immune system. Stem cell research in autism is being conducted at several regenerative medicine research
centers including the California Institute of Regenerative Medicine (CIRM).
Cell Therapeutics, Inc.
Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and
commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company
of TelAvivUniversity. For more information, visit the company's website at www.brainstorm-cell.com.
Safe Harbor Statement
announcement other than historical data and information constitute "forward-looking statements" and involve risks and
uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied
by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could",
"will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to identify these forward-looking
statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited
operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately
protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals;
and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov.
These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking
statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and
opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements
to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, levels of activity, performance or achievements.
Cell Therapeutics Inc. (OTC.QB: BCLI)
Dr. Tony Fiorino, CEO
Phone: +972-3-923-6384
LifeSci Advisors, LLC